

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 893 506 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

27.01.1999 Bulletin 1999/04

(51) Int. Cl.⁶: **C12N 15/56**, **C12N 9/24**

(21) Application number: **97908558.6**

(86) International application number:

PCT/JP97/01111

(22) Date of filing: **31.03.1997**

(87) International publication number:

WO 97/38113 (16.10.1997 Gazette 1997/44)

(84) Designated Contracting States:

**AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE**

(30) Priority: **05.04.1996 JP 84326/96**

30.04.1996 JP 109663/96

(72) Inventors:

- **TANO, Naoki**
Midorimachi Owariasahi-shi Aichi 488 (JP)
- **KIMATA, Koji**
Aichi 468 (JP)

(71) Applicant: **Seikagaku Corporation**

Chuo-ku, Tokyo 103-0023 (JP)

(74) Representative:

Bannerman, David Gardner et al
Withers & Rogers,
4 Dyer's Buildings,
Holborn
London EC1N 2QP (GB)

(54) **POLYPEPTIDE OF HUMAN-ORIGIN HYALURONATE SYNTHETASE AND DNA ENCODING THE SAME**

(57) A DNA encoding at least part of a hyaluronan synthase of human origin, particularly encoding the whole or a part of an amino acid sequence shown by SEQ ID NO: 4. A polypeptide of the hyaluronan synthase of human origin, which is encoded by the DNA, may have a substitution, deletion or insertion of one or more amino acid residues that does not substantially lower an activity of synthesizing hyaluronan. A polypeptide of the hyaluronan synthase of human origin or a part thereof encoded by the DNA is also provided.

EP 0 893 506 A1

Description

Technical Field

5 The present invention relates to a polypeptide of a hyaluronan synthase of human origin and a DNA encoding the same.

Background Art

10 Hyaluronan is one of high molecular weight glycosaminoglycans and is constituted by repeated β -1,4 linked disaccharide units, each of the unit being composed of glucuronic acid linked to N-acetylglucosamine by a β -1,3 bond (GlcUA β 1-3GlcNAc; GlcUA and GlcNAc represent glucuronic acid and N-acetylglucosamine, respectively). Hyaluronan is a characteristic constituent of the extracellular matrix at the early stage of morphogenesis of animals. Its synthesis is regulated spatially and temporally (Toole, B.P. (1981) Cell Biology of the Extracellular Matrix (Hey, E.D., ed.) pp. 259-294, Plenum, New York). Accumulation of hyaluronan on the cell surface is correlated with regulation of behavior of cells, particularly migration, adhesion, cure of wounds, infiltration of tumors, and the like (Turley, E.A. (1989) The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp. 121-137; Wiley, Chichester, England; Knudson, W., Biswas, C., Li, X.-Q., Nemec, R.E., and Tool, B.P. (1989) The Biology of Hyaluronan, Ciba Foundation Symposium 143, pp. 150-169, Wiley, Chichester, England; Laurent, T.C., and Fraser, J.R.E. (1992) FASEB J. 6, 2397-2404; Kimata, K., Honma, Y., Okayama, M., Oguri, K., Hozumi, M., and Suzuki, S. (1983) Cancer Res. 43, 1347-1354).

20 Biosynthesis of hyaluronan has been widely studied using a procaryote, *Streptococci*. A recent report revealed that a structural gene of hyaluronan synthase derived from *Streptococcus pyogenes* which is a procaryote was isolated (DeAngelis, P.L., Papaconstantinou, J., and Weigel, P.H. (1993) J. Biol. Chem. 268, 19181-19184). In contrast, little is known about the biosynthesis mechanism of hyaluronan in eucaryotes. Attempts have been made to purify eucaryotic hyaluronan synthase. However, some reports showed that the obtained enzyme lost its activity (Mian, N. (1986) Biochem. J. 237, 343-357; Ng, K.F., and Schwartz, N.B. (1989) J. Biol. Chem. 264, 11776-11783; Klewes, L., Turley, E.A., and Prehm, P. (1993) Biochem. J. 290, 791-795). Any DNA encoding a polypeptide of eucaryotic hyaluronan synthase is not known.

25 If a polypeptide of hyaluronan synthase derived from eucaryotes, particularly human, and a DNA encoding it are obtained, they would be useful for treatments, including gene therapy, of diseases caused by decreased expression of hyaluronan in humans. In addition, these substances would also be useful for gene therapy for suppressing metastasis of cancer using an antisense DNA, RNA, or the like as well as development of hyaluronan synthase-specific inhibitors.

Disclosure of the Invention

35 The object of the present invention is to provide a polypeptide of a hyaluronan synthase of human origin and a DNA encoding the polypeptide.

The present inventors intensively investigated to achieve the above object and, as a result, succeeded in cloning a cDNA encoding a polypeptide of hyaluronan synthase, which has hyaluronan synthase activity, from cells of an organism except human and, by using a fragment derived from the cDNA, cloning a cDNA encoding a polypeptide of a hyaluronan synthase of human origin. Thus, the present invention was completed.

The present invention provides a DNA encoding the following polypeptide (a) or (b):

- 45 (a) a polypeptide of a hyaluronan synthase of human origin; and
(b) a partial polypeptide of the polypeptide (a).

Further, the present invention also provides a DNA encoding any one of the following polypeptides (a) to (c):

- 50 (a) a polypeptide having the amino acid sequence shown by SEQ ID NO: 4;
(b) a polypeptide having the amino acid sequence shown by SEQ ID NO: 4, which has a substitution, deletion or insertion of one or more amino acid residues that does not substantially lower an activity of synthesizing hyaluronan; and
(c) a partial polypeptide of the polypeptide (a) or (b).

55 The above-described DNA preferably encodes the whole or the amino acid sequence shown by SEQ ID NO: 4. It also preferably has at least a part of the nucleotide sequence shown by SEQ ID NO: 1, more preferably has a nucleotide sequence of from position 149 to position 1777 of the nucleotide sequence shown by SEQ ID NO: 1. In the present invention, the DNA of the present invention includes a DNA or an RNA complementary to the DNA.

Furthermore, the present invention provides a polypeptide of a hyaluronan synthase of human origin or a part thereof (hereinafter referred to "the polypeptide of the present invention") encoded by the above-described DNA of the present invention.

The term "part of the polypeptide" used herein means a part having an activity or function such as hyaluronan synthase activity and immunogenicity, or a part, the nucleotide sequence of which is specific to the hyaluronan synthase and can be used as a primer or a probe.

Further, the term "at least part of the nucleotide sequence" used herein means a part encoding a part of the polypeptide having an activity or function such as hyaluronan synthase activity and immunogenicity, or the part which is specific to the hyaluronan synthase and can be used as a primer or a probe.

The following explains the embodiments of the present invention in detail.

I. The DNA of the present invention

The DNA of the present invention is the one encoding at least part of a polypeptide of a hyaluronan synthase of human origin, specifically one encoding at least part of a polypeptide having the amino acid sequence shown by SEQ ID NO: 4. The polypeptide of the hyaluronan synthase of human origin or the polypeptide having the amino acid sequence shown by SEQ ID NO: 4, which is encoded by the DNA of the present invention, may have a substitution, deletion or insertion of one or more amino acid residues that does not substantially lower the activity of synthesizing hyaluronan. The DNA of the present invention is preferably a DNA encoding at least part of the polypeptide of a hyaluronan synthase of human origin, and encoding the whole or a part of the amino acid sequence shown by SEQ ID NO: 4, or a DNA encoding at least part of the polypeptide of the hyaluronan synthase of human origin, which has the amino acid sequence shown by SEQ ID NO: 4, in which a substitution, deletion or insertion of one or more amino acid residues that does not substantially lower the activity of synthesizing hyaluronan may be present. More preferably, the DNA of the present invention is a DNA encoding the whole of the amino acid sequence shown by SEQ ID NO: 4. The DNA of the present invention is still more preferably a DNA having at least part of the nucleotide sequence shown by SEQ ID NO: 1. A specific example of the DNA is one having the nucleotide sequence of from position 149 to position 1777 of the nucleotide sequence shown by SEQ ID NO: 1. The DNA of the present invention may have a substitution, deletion, or insertion of one or more nucleotides as long as it has substantially the same nucleotide sequence as shown by SEQ ID NO: 1 and does not substantially lower the hyaluronan-synthesizing activity of the polypeptide of hyaluronan synthase encoded by the above nucleotide sequence. In other words, the DNA of the present invention includes DNA encoding a polypeptide of hyaluronan synthase having the above-described substitution, deletion, or insertion of nucleotide(s).

A specific example of the DNA of the present invention is a DNA having the nucleotide sequence of from position 149 to position 1777 of the nucleotide sequence shown by SEQ ID NO: 1. One of ordinary skill in the art would readily understand that the DNA of the present invention include DNAs having the nucleotide sequences different from that as described above due to degeneracy of the genetic codes.

Also, the DNA of the present invention may be either a coding single strand encoding only the polypeptide of hyaluronan synthase or a double-stranded chain composed of the above single strand and a DNA strand having complementary sequence thereto.

Since the nucleotide sequence of the DNA of the present invention was revealed by the present invention, the DNA can be synthesized based on the sequence. The DNA is also obtained by amplifying the DNA of the present invention from human chromosomal DNA or mRNA by polymerase chain reaction (PCR) method using oligonucleotide primers prepared based on the sequence. The DNA of the present invention was obtained for the first time by the cDNA cloning comprising the following steps as also described in the example below.

(1) Cloning of a cDNA encoding a polypeptide of a hyaluronan synthase of mouse origin:

- i) selection of mouse cells capable of high level production of hyaluronan and preparation of mouse mutant cells deficient in hyaluronan-synthesizing ability;
- ii) isolation of a poly(A)⁺ RNA containing an mRNA corresponding to the polypeptide of hyaluronan synthase;
- iii) construction of a mouse cDNA library;
- iv) introduction of the cDNA library constructed in iii) into the mutant cells deficient in hyaluronan-synthesizing ability prepared in i) (transfection);
- v) selection of cells capable of synthesizing hyaluronan from the cells transformed in iv);
- vi) Recovery of a plasmid DNA from the cells selected in v), transformation of *Escherichia coli* cells with the plasmid DNA, and recovery of the plasmid DNA from the *E. coli* cells; and
- vii) isolation of a cDNA encoding the polypeptide of the hyaluronan synthase of mouse origin by repeating three more times the above steps iv) to vi) using the recovered plasmid DNA.

(2) Cloning of a cDNA encoding a polypeptide of the hyaluronan synthase of human origin:

- i) preparation of a probe for screening a human cDNA library based on the result of sequencing of the cDNA isolated in vii) of (1) above;
- ii) screening of cDNA clones of human hyaluronan synthase using the probe prepared in i); and
- iii) nucleotide sequencing.

The method of producing the DNA of the present invention is not to be limited to the above method. The DNA of the present invention can be prepared by PCR method as described above or other known cDNA cloning methods.

An example of the method of producing the DNA of the present invention is described in detail below.

1. Cloning of a cDNA encoding a polypeptide of hyaluronan synthase derived from an organism except human

(1) Selection of cell lines capable of high level production of hyaluronan and preparation of mutant cells deficient in hyaluronan-synthesizing ability

(1-1) Selection of cells capable of high level production of hyaluronan

Cells capable of high level production of hyaluronan (hereinafter also simply referred to as "high level hyaluronan-producing cells") are selected using cells of an organism except human having the hyaluronan synthase activity. Though the cells of an organism except human having the hyaluronan synthase activity are not particularly limited, eucaryotic cells are preferable, mammalian cells are more preferable, and mouse cells are particularly preferable. Established cultured cell lines (hereinafter also simply referred to as "cell line") are preferably used in view of availability, easiness to handle, and ability to proliferate. Mouse-derived cell lines are more preferable. Among the mouse-derived cell lines, FM3A, a mouse mammary carcinoma cell line (Health Science Research Resources Bank; cell number, JCRB0701, or RIKEN Cell Bank; cell number, RCB0086) is particularly preferable. Furthermore, among FM3A, FM3A P15A that is a cell line selected taking high metastatic ability to lung as an index (Honma, Y., Kasukabe, T., and Hozumi, M. (1981) Gann 72, 898-905; Kimata, K., Honma, Y., Okayama, M., Oguri, K., Hozumi, M., and Suzuki, S. (1983) Cancer Res. 43, 1347-1354) is most preferable because of its high hyaluronan synthase activity.

Culture media used for culturing the above-described cultured cells are not particularly limited as long as cells can grow therein. Any media known in the field of cell culture can be used. For example, Eagle's minimum essential medium or the like is preferable since it has been widely used in usual culturing, readily available, and allows the above-described cells to grow. The pH of the medium is adjusted preferably to the neutral region, particularly to pH 7.0. Heat-inactivated bovine serum is preferably added to the medium to about 10%. Furthermore, amino acids and vitamins are preferably added to the medium in the order of double with respect to the usual amounts. Substances such as penicillin and streptomycin can be added to prevent proliferation of contaminating microorganisms. The above-described cells can be maintained or proliferated with the above medium in a dish or a roller bottle by the usual culturing method. The culture can be preferably performed in a carbon dioxide incubator; the concentrations of carbon dioxide and air in the incubator are preferably adjusted to 3 to 7% and 97 to 93%, respectively. The temperature is preferably adjusted to about 37 to 38°C.

The method of selecting the high level hyaluronan-producing cells is not particularly limited as long as it enables evaluation of the hyaluronan-producing ability of the cells. For example, a method utilizing fixed erythrocyte exclusion assay (Knudson, W. and Knudson, C.B. (1991) J. Cell. Sci. 99, 227-235) can be used. In the fixed erythrocyte exclusion assay, the degree of formation of extracellular hyaluronan matrix can be observed taking as an index the distance that fixed erythrocytes cannot come close to the cells. More specifically, the longer the distance that fixed erythrocytes cannot come close to the cells is, the thicker the hyaluronan matrix is formed. The hyaluronan-producing ability of the cells can be evaluated by observing the degree of formation of extracellular hyaluronan matrix using the fixed erythrocyte exclusion assay. The example as described below specifically demonstrates the fixed erythrocyte exclusion assay.

The high level hyaluronan-producing cells as selected in the above method are used in the preparation of a poly(A)⁺ RNA.

(1-2) Preparation of mutant cells deficient in the hyaluronan-synthesizing ability

Mutant cells deficient in the hyaluronan-synthesizing ability (hereinafter also simply referred to as "cells incapable of synthesizing hyaluronan") can be obtained by mutagenizing the high level hyaluronan-producing cells as selected in (1-1) above by exposing the cells to physical or chemical stimulation to some extent that the cells do not die. The physical stimulation includes, for example, treatment with radiation such as X-ray or γ -ray. The chemical stimulation includes treatment with a mutagen such as an alkylating agent. Preferable alkylating agents include nitrosoguanidine and its

derivatives, for example, N-methyl-N'-nitro-N-nitrosoguanidine or the like. When N-methyl-N'-nitro-N-nitrosoguanidine is used as a mutagen, its concentration is preferably about 0.5 µg/ml. The cells incapable of synthesizing hyaluronan can be selected and recovered from the cells mutagenized by the above method, according to a method for evaluating the hyaluronan-producing ability, such as the fixed erythrocyte exclusion assay (described in detail in the following example).

(1-3) Preparation of cells incapable of synthesizing hyaluronan used as a host into which a recombinant DNA is transfected

When the cells incapable of synthesizing hyaluronan prepared in (1-2) above are used as a host into which a recombinant DNA is transfected as in (4) shown below, the cells have been preferably transformed so as to express polyoma large T antigen. For the transformation, the cells have been preferably transformed with a plasmid carrying the polyoma T antigen gene. An example of the plasmid carrying the polyoma T antigen gene is pdl3027 plasmid (Nagata, Y., Yamashiro, S. Yodoi, J., Lloyd, K.O, Shiku, H., and Furukawa, K. (1992) J. Biol. Chem. 267, 12082-12089). The thus-obtained cells incapable of synthesizing hyaluronan and expressing polyoma large T antigen (hereinafter also simply referred to as "T antigen-expressing cells incapable of synthesizing hyaluronan") can be used in (4) below as a host into which a recombinant DNA is transfected.

(2) Isolation of a poly(A)⁺ RNA containing an mRNA corresponding to the polypeptide of hyaluronan synthase from the high level hyaluronan-producing cells prepared in (1-1) above

(2-1) Preparation of the total RNA

The total RNA can be obtained by the known method (Kingston, R.E. (1991) Current Protocols in Molecular Biology, Suppl. 14, Unit 4.2, Greene Publishing Associates and Wiley Interscience, New York, etc.). Although a total RNA can be obtained from the high level hyaluronan-producing cells prepared in (1-1) above by the method usually used for preparing a total RNA, a preferable method includes the guanidine thiocyanate/CsCl method (Kingston, R.E. (1991) Current Protocols in Molecular Biology, Suppl. 14, Unit 4.2, Greene Publishing Associates and Wiley Interscience, New York).

(2-2) Preparation of a poly(A)⁺ RNA

A poly(A)⁺ RNA can be purified from the total RNA obtained in (2-1) above by oligo-(dT) cellulose column chromatography or the like.

(3) Preparation of a cDNA library

(3-1) Synthesis of cDNA

cDNA can be synthesized by the reverse transcriptase reaction using the poly(A)⁺ RNA prepared in (2) above as a template. Specifically, the methods usually used in the field of gene engineering may be used. Alternatively, a commercially available cDNA synthesizing kit may be used. Though oligo(dT), which is usually used as a primer, can be used as a primer in the reverse transcriptase reaction, a random oligo nucleotide primer is preferably used.

(3-2) Preparation of a cDNA library

A cDNA library can be obtained by ligating the cDNA obtained in (3-1) above to a cloning vector.

Although the cloning vector to which the cDNA is ligated is not particularly limited, an expression vector functioning in mammalian cells is preferably used. In order to make the subsequent procedure readily operable, it is preferable to use a shuttle vector having a replication origin functioning in cells such as *Escherichia coli* (*E. coli*). A preferable vector may be pcDNA1 (manufactured by Invitrogen Co.). The cDNA obtained in (3-1) above is ligated to the above-described cloning vector to give a recombinant DNA (cDNA library).

(4) Transfection of the recombinant DNA prepared in (3) above into the cells incapable of synthesizing hyaluronan

The recombinant DNA (cDNA library) obtained by ligating the cDNA to the cloning vector is transfected into host cells. The host cells to be used should be selected depending on the cloning vector used. For example, when an expression vector functioning in mammalian cells is used as a cloning vector, host cells should be mammalian cells.

Alternatively, the cDNA library may be prepared by selecting host cells first and then selecting a cloning vector suitable for the host cells.

When cloning is performed using the presence of hyaluronan-synthesizing ability as an index, it is preferable to use as host cells the cells incapable of synthesizing hyaluronan as prepared in (1) above. The T antigen-expressing cells incapable of synthesizing hyaluronan prepared in (1-3) above are most preferably used.

The DNA can be transfected into the host cells by the method usually used in the field of gene engineering. A commercially available reagent for transformation can also be used. As such a reagent, Lipofectoamine™ reagent (Life Technologies, Inc) is suitably used. The transformed T antigen-expressing cells incapable of synthesizing hyaluronan are cultured using the medium and the method as described in (1-1) above. Though the culturing period is not particularly limited, about 64 hours are preferable.

(5) Selection of cells capable of synthesizing hyaluronan from transformants obtained in (4) above

(5-1) Preparation of labeled hyaluronan-binding protein used for detecting hyaluronan

Among the host cells into which the cDNA library has been transfected, the T antigen-expressing cells incapable of synthesizing hyaluronan, into which the recombinant DNA containing the cDNA encoding the polypeptide of hyaluronan synthase has been transfected, express the polypeptide of hyaluronan synthase by culturing the cells by the method as described in (4) above so that hyaluronan can be synthesized and accumulated extracellularly. The T antigen-expressing cells incapable of synthesizing hyaluronan, into which the recombinant DNA containing cDNA encoding the polypeptide of hyaluronan synthase has been transfected, can be selected by detecting cells in which hyaluronan is accumulated extracellularly. Though the method of detecting extracellularly accumulated hyaluronan is not particularly limited, the detection is preferably performed by using a protein capable of binding to hyaluronan (herein also referred to as "hyaluronan-binding protein") that is labeled (herein also referred to as "labeled hyaluronan-binding protein"). The hyaluronan-binding protein is not particularly limited. Examples thereof include aggrecan, neurocan, versican, link protein, hyaluronectin, hyaluronan-binding protein derived from human synovial fluid, brain hyaluronan-binding protein, and CD44. Among these, aggrecan is preferably used. Particularly, the hyaluronan-binding region of aggrecan (herein also abbreviated as "HABR") is preferably used.

A substance used to label the hyaluronan-binding protein is not particularly limited. Examples thereof include biotin, avidin (including streptoavidin), fluorescent substances, enzymes, and radioisotopes. Biotin is preferably used. The method of labeling the hyaluronan-binding protein using the above labels is not particularly limited. A known labeling method can be used.

When biotin is used to label the hyaluronan-binding protein, for example, avidin labeled with a fluorescent substance is used to detect the biotin. A commercially available labeled avidin can also be used. Further, biotinated HABR, which is an example of the labeled hyaluronan-binding protein, will be described in the following example for its specific preparation method.

(5-2) Selection of cells capable of synthesizing hyaluronan

The T antigen-expressing cells incapable of synthesizing hyaluronan transformed in (4) above are contacted with the labeled hyaluronan-binding protein obtained in (5-1) above and the mixture is incubated. The cells capable of synthesizing hyaluronan can be selected by detecting and selecting cells in which hyaluronan is accumulated extracellularly. Further, when the hyaluronan-binding protein is labeled with biotin, the cells need to be incubated with labeled avidin to contact together after incubation with the biotin-labeled hyaluronan-binding protein. The cells are preferably washed after every incubation. The incubation conditions are not particularly limited as long as binding of hyaluronan to the hyaluronan-binding protein is not inhibited. Preferably, the incubation is performed at a neutral pH and on ice (0°C). Though the incubation period is not also particularly limited, it is preferably about 1 hour.

After the incubation, a known detection method for the label is suitably selected depending upon the type of the label used, thereby detecting cells (positively stained cells) on which the label is found extracellularly (on the cell surface). Thus, the cells capable of synthesizing hyaluronan can be selected. When a fluorescent substance is used as a label, detection of the label and selection of the cells can be concurrently done by means of flow cytometry.

(6) Recovery of a plasmid DNA from the cells selected in (5) above, transformation of *E. coli* with the recovered plasmid DNA, and recovery of the plasmid DNA from the transformed *E. coli*

A plasmid DNA (a recombinant DNA) is recovered from the cells capable of synthesizing hyaluronan selected in (5) above and the resulting recombinant DNA is used to transform *Escherichia coli* (*E. coli*). The method of recovering plasmid DNA is performed with the commonly used technique in the field of gene engineering. It is not particularly limited

thereto, but the method of Hirt (Hirt, B. (1967) J. Mol. Biol. 26, 365-369) is preferably used.

E. coli is transformed with the recovered DNA and cultured by the usual method for culturing *E. coli*. The plasmid DNA (recombinant DNA) is then recovered from the resulting *E. coli*.

(7) Isolation of the cDNA

As described above, the cDNA encoding the polypeptide of hyaluronan synthase can be isolated. In order to confirm that the cDNA obtained actually encodes the polypeptide of hyaluronan synthase, the above steps (4) to (6) are preferably repeated about three more times.

The cDNA thus obtained is subjected to sequencing as it is or after subcloned into an appropriate plasmid. 2. Cloning of the cDNA encoding the polypeptide of human hyaluronan synthase

(1) Preparation of probes for screening of the cDNA library

The nucleotide sequence of the cDNA corresponding to the polypeptide of hyaluronan synthase derived from an organism except human determined as described above is compared with that of the cDNA of hyaluronan synthase derived from a microorganism, preferably *Streptococcus* to determine the regions that are conserved (herein also simply referred to as "conserved regions"), which can be used as a 5' primer and a 3' primer in polymerase chain reaction (PCR). Thereafter, each conserved region is synthesized.

Labeled DNA probes used for screening the cDNA library can be prepared by the DNA labeling method usually used in the field of gene engineering using the primers prepared based on the conserved regions (the 5' primer and the 3' primer) from the hyaluronan synthase gene derived from an organism except human as obtained in the item 1 above. In present invention, a radioisotope and a fluorescent substance can be used as a label. A fluorescent substance is preferably used. The labeled DNA probe can be efficiently prepared in a large quantity by PCR.

(2) Screening of clones of cDNA of human hyaluronan synthase using the probes prepared in (1) above

(2-1) Preparation of a cDNA library

A total RNA is prepared from cells derived from human and a poly(A)⁺ RNA is prepared from the total RNA. A cDNA can be synthesized by the reverse transcriptase reaction using the poly(A)⁺ RNA as a template. These procedures are all performed by the methods usually used in the field of gene engineering. Specifically, the methods as described in (2) and (3) in item 1 above may be used.

The cDNA is ligated to a cloning vector. Though the cloning vector is not particularly limited, for example, λ gt11 digested with EcoRI is preferably used. Alternatively, a commercially available human cDNA-ligated cloning vector may be used.

During the process for achieving the present invention, cDNA clones of human hyaluronan synthase were selected, as demonstrated in the example, from a human cDNA library using probes prepared based on the mouse cDNA sequence. The cDNA can be ligated to an expression vector functioning in mammalian cells and selected using the expression product as an index.

(2-2) Screening of the cDNA clones of human hyaluronan synthase

From the cDNA library obtained as described above, phage clones having the full-length of the cDNA of hyaluronan synthase can be selected by hybridization using the probe prepared in (1) above. The hybridization can be performed by the method usually used in the field of gene engineering, for example, plaque hybridization or the like. Plaques that hybridize with the probe can be isolated and identified by detecting the label bound to the probe. One of ordinary skill in the art can appropriately detect the label depending on the label used.

(3) Sequencing

A phage DNA is prepared from positive λ gt11 clones selected in (2) above and digested with an appropriate restriction enzyme to cleave out the cDNA of hyaluronan synthase. The enzyme used for cloning the cDNA is used as the restriction enzyme. For example, when λ gt11 digested with EcoRI is used as the vector, EcoRI is preferably used. The thus-obtained cDNA is subjected to sequencing as it is or after subcloned into an appropriate plasmid. When the cDNA is subcloned, pcDNA3 plasmid vector (manufactured by Invitrogen Co.) is preferably used.

The DNA as obtained above may have a substitution, deletion, or insertion of nucleotide(s) or the combination thereof, which result in substitution, deletion, or insertion of one or two or more amino acid residues of the polypeptide

of hyaluronan synthase encoded by the DNA as long as the hyaluronan-synthesizing activity of the polypeptide is not substantially lowered. The substitution, deletion, or insertion of the nucleotides can be introduced in the DNA sequence by synthesizing a sequence having restriction enzyme cleavage sites at the both ends and containing the both sides of the mutated site and replacing it with the corresponding non-mutated DNA sequence. The site-directed mutation method (Kramer, W. and Frits, H.J. (1987) Meth. in Enzymol. 154, 350; Kunkel, T.A. et al. (1987) Meth. in Enzymol. 154, 367) or the like can also be used for introducing the substitution, deletion, or insertion, or the combination thereof into the DNA sequence.

The method of measuring the hyaluronan-synthesizing activity is well known in the art. Thus, one of ordinary skill in the art would readily determine the substitution, deletion, or insertion, or the combination thereof that does not substantially lower the hyaluronan-synthesizing activity.

II. The polypeptide of the present invention

The polypeptide of the present invention is a polypeptide of the hyaluronan synthase of human origin or a part thereof, which is encoded by the DNA of the present invention. It is preferably a polypeptide of the hyaluronan synthase having the amino acid sequence (amino acid numbers 1 to 543) shown by SEQ ID NO: 4.

Since the amino acid sequence is revealed by the present invention, the polypeptide of the present invention can be synthesized based on the amino acid sequence. It is possible and preferable, however, to obtain the polypeptide by expressing the DNA of the present invention.

For example, the DNA of the present invention is ligated to an appropriate expression vector functioning in mammalian cells and cells carrying this vector are cultured in an appropriate medium to produce and accumulate the polypeptide of hyaluronan synthase in the culture (in the cells and/or the medium). The polypeptide of hyaluronan synthase is then extracted from the culture. In this way, the polypeptide of hyaluronan synthase can be produced. In this procedure, the usually used methods for extracting and purifying enzymes can be used.

Specifically, examples of the extraction method include cell disruption due to, for example, ultrasonication, homogenization, osmotic shock procedure, freezing and thawing method, treatment with a surfactant, and the combined process thereof. Further, specific examples of the purification methods include salting out with ammonium sulfate or sodium sulfate, centrifugation, dialysis, ultrafiltration, adsorption chromatography, ion exchange chromatography, hydrophobic chromatography, reverse phase chromatography, gel filtration, gel permeation chromatography, affinity chromatography, electrophoresis, and the combined process thereof.

The DNA of the present invention can be expressed using a host-vector system usually used for producing proteins. The host-vector system is preferably an animal cell system, particularly, a mammalian cell system. The DNA of the present invention may be expressed alone or as a fusion protein together with another protein. The full-length of the DNA may be expressed. Alternatively, part of the DNA may be expressed to produce a partial peptide.

The polypeptide of hyaluronan synthase as produced above or its partial peptide, or a fusion protein thereof with another protein can be used to produce antibodies that bind to the hyaluronan synthase. The antibodies can be prepared by the usual methods for producing antibodies. Monoclonal antibodies that bind to the hyaluronan synthase can also be produced by the usual methods.

Best Mode of Carrying out the Invention

The present invention will be described in more detail with reference to the following example.

First, the methods commonly used throughout the example are described.

1. Fixed erythrocyte exclusion assay

Cells were inoculated on a 35-mm tissue culture dish and cultured at 37°C for 3 days. The culture medium was replaced with 750 μ l of a suspension of fixed sheep erythrocytes (manufactured by Inter-Cell Technologies, Inc.) (10^8 cells/ml). After the dish was allowed to stand for 10 minutes, extracellular hyaluronan matrix were observed as the region that the erythrocytes could not come close to. The observation was performed using a phase-contrast microscope (OLYMPUS IMT-2; manufactured by Olympus Optical Co.) with 200-fold magnification.

2. Preparation of biotinated hyaluronan-binding region (b-HABR)

Aggrecan was extracted from bovine nasal cartilage with a guanidine solution and purified by cesium chloride density gradient centrifugation under association and dissociation conditions. The hyaluronan-binding region of the purified aggrecan (2 mg) was protected by hyaluronan and the protected aggrecan was reacted with 0.57 mg of NHS-LC-biotin (manufactured by Pierce) at room temperature for 2 hours for biotination. The biotinated aggrecan was partially

digested with trypsin and the digested product was subjected to gel filtration using a Sephacryl S-300 column (manufactured by Pharmacia) and then hyaluronan affinity chromatography (Tengblad, A. (1979) Biochem. Biophys. Acta 578, 281-289). Thus, b-HABR was purified.

A production example of the DNA of the present invention is described below.

1. Cloning of a cDNA encoding a polypeptide of a hyaluronan synthase of mouse origin

(1) Selection of high level hyaluronan-producing cells and preparation of cells incapable of synthesizing hyaluronan

(1-1) Selection of high level hyaluronan-producing cells

FM3A P-15A having high metastatic ability to lung was selected and established as a cell line derived from mouse mammary carcinoma cell line FM3A (Health Science Research Resources Bank; cell number, JCRB0701), which is one of mouse-derived established cell lines. FM3A P-15A cells were cultured in Eagle's minimum essential medium (manufactured by Nissui Pharmaceutical) containing 10% heat-inactivated bovine serum, doubled concentrations of amino acids and vitamins, penicillin, and streptomycin in a 100-mm petri dish (manufactured by Falcon. No. 1005). Culture was performed under the condition of 37°C in 5% CO₂.

The degree of formation of extracellular hyaluronan matrix in the FM3A P-15A culture was examined by the fixed erythrocyte exclusion assay. Cells that extracellularly formed hyaluronan matrix in a larger amount compared with the other cells were collected and pooled. The resulting cells (high level hyaluronan-producing cells) were designated as FM3A HA1.

(1-2) Preparation of cells incapable of synthesizing hyaluronan

The high level hyaluronan-producing cells selected in (1-1) above were treated with 0.5 µg/ml of N-methyl-N'-nitro-N-nitrosoguanidine (manufactured by Nacalai Tesque Co.) and examined for the degree of formation of extracellular hyaluronan matrix by fixed erythrocyte exclusion assay. Cells that did not extracellularly form hyaluronan matrix were collected and pooled. The thus-obtained cells incapable of synthesizing hyaluronan were designated as HAS⁻ cells.

(1-3) Preparation of HAS⁻ cells that express polyoma large T antigen

Plasmid pdl3027 containing the polyoma T antigen gene (given by Dr. K. Furukawa (Nagasaki University) and Dr. C. Basilio (New York University)) and plasmid pSV2neo (manufactured by CLONTECH Co.) were transfected into HAS⁻ cells as obtained above. The cells were selected through treatment with 500 µg/ml G-418 (manufactured by Gibco Co.). Thus, HAS⁻ cells that constantly express polyoma large T antigen (herein also referred to as "HAS-P cells") were prepared.

(2) Isolation of a poly(A)⁺ RNA from FM3A HA1

(2-1) Preparation of a total RNA

A total RNA was prepared from FM3A HA1 by the guanidine thiocyanate/CsCl method (Kingston, R.E. (1991) Current Protocols in Molecular Biology, Suppl. 14, Unit 4.2, Greene Publishing Associates and Wiley Interscience, New York).

(2-2) Preparation of a poly(A)⁺ RNA

A poly(A)⁺ RNA was purified from the total RNA obtained in (2-1) above by oligo-(dT) cellulose column chromatography.

(3) Preparation of a cDNA library

(3-1) Synthesis of cDNA

cDNA was synthesized by reverse transcriptase reaction using the poly(A)⁺ RNA obtained in (2-2) above as a template, and random oligonucleotide primers as primers.

(3-2) Preparation of a cDNA library

The cDNA obtained in (3-1) above was ligated to pcDNA1 (manufactured by Invitrogen Co.), an expression vector functioning in mammalian cells, to prepare a cDNA library.

(4) Transformation by the cDNA library

The cDNA library prepared in (3-2) above was transfected into HAS-P cells prepared in (1-3) above using Lipofectamine™ reagent, manufactured by Life Technologies, Inc. The transformed HAS-P cells were cultured in the medium under the conditions as described in (1-1) above for 64 hours.

(5) Selection of cells capable of synthesizing hyaluronan from transformants

After 64-hour culturing as described in (4) above, the transformants were washed with a cooled medium (Cosmedium001 (manufactured by Cosmo Bio)) and then suspended in the same medium but containing 50 µg/ml of b-HABR. After 1 hour, the cells were washed with cooled Cosmedium001 and suspended in the same medium but containing avidin labeled with fluorescein (fluorescein avidin DCS, manufactured by Vector Laboratories, Inc.). After 1 hour, the cells were washed with cooled phosphate-buffered saline (PBS) containing 5% fetal calf serum and suspended in the same solution. Positively stained cells were selected using a flow cytometer (EPICS Elite Flow Cytometer, manufactured by Coulter Electronics, Inc.).

(6) Recovery of a plasmid DNA from the cells selected in (5) above, transformation of *E. coli* with the recovered plasmid DNA, and recovery of the plasmid DNA from *E. coli* transformants

A plasmid DNA was recovered from the cells selected in (5) above by the method of Hirt (Hirt, B. (1967) J. Mol. Biol. 26, 365-369). Specifically, this procedure was performed in the following manner. The cells selected in (5) above were dissolved in 100 µl of 0.6% sodium dodecyl sulfate (SDS)/10 mM ethylenediamine-tetraacetic acid (EDTA) solution and the mixture was allowed to stand at the room temperature for 20 minutes. Twenty-five ml of 5M NaCl was then added thereto and the mixture was allowed to stand overnight on ice. The solution was treated with phenol and chloroform and then precipitated with ethanol to recover a plasmid DNA. The recovered plasmid DNA was used to transform *E. coli* MC1061/P3 (manufactured by Invitrogen Co.) by electroporation. The resulting transformants were cultured and the plasmid DNA was then recovered therefrom.

(7) Isolation of the cDNA encoding the polypeptide of hyaluronan synthase

The above steps (4) to (6) (steps of transformation and selection) were repeated three more times using the plasmid DNA recovered from the transformed *E. coli* MC1061/P3 obtained in (6) above to isolate cDNA encoding the polypeptide of hyaluronan synthase. The thus-isolated cDNA encoding the polypeptide of hyaluronan synthase was designated as pcDNA1-HAS.

(8) Determination and analysis of the cDNA sequence encoding the polypeptide of hyaluronan synthase

The cDNA clone isolated in (7) above was subcloned into a plasmid vector, pcDNA3 (manufactured by Invitrogen Co.). The thus-obtained recombinant plasmid was designated as pcDNA3-HAS. pcDNA3-HAS was denatured with alkali and its nucleotide sequence of both sense and antisense directions was determined using [³⁵S]dCTP and deazaGTP kit (manufactured by U.S. Biochemical Co.) and DNA polymerase (Sequenase ver 2.0, manufactured by U.S. Biochemical Co.).

DNA synthesis for sequencing was performed using primers synthesized based on T7, SP6, and the nucleotide sequence existing at about 250 bp intervals in pcDNA3. The thus-obtained DNA sequence was analyzed by GENE-TYX-MAC computer program (manufactured by Software Development Co.). The nucleotide sequence and the deduced amino acid sequence therefrom were analyzed utilizing a database for analyzing nucleic acids and proteins (EMBL-GDB, Release44, and NBRF-PDB, Release 45). The amino acid sequence of the polypeptide of hyaluronan synthase originating from *Streptococcus* (*Streptococcus pyogenes*) was compared with that of the polypeptide of the hyaluronan synthase originating from mouse. Two regions that conserved in both of the polypeptides of hyaluronan synthase were found and designated as HAS-1 and HAS-2, respectively. The nucleotide sequences corresponding to these regions are shown by SEQ ID NO: 2 (HAS-1) and SEQ ID NO: 3 (HAS-2).

2. Production of the DNA of the present invention

(1) Preparation of probes for screening a human cDNA library

5 An oligonucleotide having the sequence of HAS-1 and that having the sequence of HAS-2 were synthesized.

Fluorescence-labeled DNA probes used for screening the cDNA library were prepared from the mouse-origin hyaluronan synthase gene obtained in the item 1 above by PCR method with ECL™ probe-amp reagents (manufactured by Amersham Co.) using primers produced based on the conserved regions (HAS-1 and HAS-2; using as a 5' primer an oligonucleotide having the sequence of HAS-1 and as a 3' primer an oligonucleotide having the sequence of HAS-2). PCR amplification was performed 30 cycles using GeneAmp PCR reagent kit (manufactured by Takara Shuzo) (Each cycle consisted of denaturation at 95°C for 1 minute, annealing at 50°C for 2 minutes, and extension at 72°C for 3 minutes.). The PCR products were analyzed by 2% agarose gel electrophoresis.

(2) Screening of the cDNA clones of human hyaluronan synthase using the probes prepared in (1)

15 For isolating a human homolog of the hyaluronan synthase gene, human fetal brain cDNA library constructed in λ gt11 (manufactured by CLONTECH) was mixed with indicator bacteria and melted soft agar. The mixture was layered on an agar plate and cultured. As a result, 1×10^6 plaques were formed.

20 The plaques derived from the λ gt11 cDNA library as obtained above were screened. The plaques were transferred onto a commercially available nylon membrane (Hybond N+™ nylon membrane, manufactured by Amersham) and the phage DNA was fixed on the nylon membrane by the alkaline fixation method recommended in the instructions appended to the product.

25 This filter was allowed to hybridize with the probes prepared in (1) above in 5 x SSC containing 0.1% SDS, 5% (w/v) dextran sulfate, and 100 μ g/ml denatured salmon sperm DNA at 60°C for 12 hours. The filter was washed with 1 x SSC containing 0.1% SDS at 60°C for 15 minutes, then 0.5 x SSC containing 0.1% SDS at 60°C for 15 minutes. Positive clones were detected with ECL™ detection kit (manufactured by Amersham).

(3) Sequencing

30 The recombinant vector was purified from the λ gt11 positive clones and digested with EcoRI to excise the cDNA insert as a single fragment. This fragment was subcloned into a plasmid vector, pcDNA3 (manufactured by Invitrogen Co.). The nucleotide sequence of the isolated cDNA was determined by repeatedly sequencing both strands of the alkali-denatured plasmid DNA using [³⁵S]dGTP and deazaGTP kit and DNA polymerase (Sequenase version 2.0, manufactured by U.S. Biochemical Co.). DNA synthesis for sequencing was started with primers synthesized based on T7, SP6, and the nucleotide sequence existing at about 250 intervals in pcDNA3. The DNA sequences obtained were compiled and analyzed using GENETYX-MAC computer program (manufactured by Software Development Co.). The nucleotide sequence and the deduced amino acid sequence therefrom were analyzed using a database for analyzing nucleic acids and proteins (EMBL-GDB, Release44, and NBRF-PDB, Release45). The determined nucleotide sequence is shown by SEQ ID NO: 1. The amino acid sequence encoded by the open reading frame existing in this nucleotide sequence (from position 149 to position 1777) is shown by SEQ ID NO: 4.

Industrial Applicability

45 The polypeptide of the present invention can be used for mass production of hyaluronan, which is used as an ingredient of medicines and cosmetics at present, in an industrial scale, and for medicines for diseases caused by decreased expression of hyaluronan. The polypeptide of the present invention can also be used for development of hyaluronan synthase-specific inhibitors. Furthermore, the polypeptide can be used as an antigen to produce antibodies specific to the hyaluronan synthase. The DNA of the present invention can be used for mass production of the polypeptide of hyaluronan synthase in an industrial scale, and for gene therapy for diseases caused by decreased expression of hyaluronan. Moreover, an antisense DNA and an antisense RNA of the DNA of present invention can be used for gene therapy for metastasis inhibitors.

The DNA of the present invention can also be used as a reagent for research purpose.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: SEIKAGAKU CORPORATION

(ii) TITLE OF INVENTION: POLYPEPTIDE OF HYALURONAN SYNTHASE OF HUMAN-
ORIGIN AND DNA ENCODING THE SAME

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SEIKAGAKU CORPORATION

(B) STREET: 1-5, Nihonbashi-honcho 2-chome

(C) CITY: Chuo-ku

(D) STATE: Tokyo

(E) COUNTRY: JAPAN

(F) ZIP: 103

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME:

(B) REGISTRATION NUMBER:

(C) REFERENCE/DOCKET NUMBER:

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE:

(B) TELEFAX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2117

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: Genomic DNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Human

(B) TISSUE TYPE: Fetal brain

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

10	GAATTCGGG CGCCCGGGAC TCACGCCCT TCCTTTCCCC TCTCGCTCCC AGCAGGACGC	60
	GCCCAAGCCC ACTCCTGCAG CCCGCCCTG CTCCGGCCTG GCCCGGAGGG TGCTGACCAT	120
	CGCCTTCGCC CTGCTCATCC TGGCCCTC ATG ACC TGG GCC TAC GCC GCC GGG	172
15	Met Thr Trp Ala Tyr Ala Ala Gly	
	1 5	
	GTG CCG CTG GCC TCC GAT CGC TAC GGC CTC CTG GCC TTC GGC CTC TAC	220
	Val Pro Leu Ala Ser Asp Arg Tyr Gly Leu Leu Ala Phe Gly Leu Tyr	
20	10 15 20	
	GGG GCC TTC CTT TCA GCG CAC CTG GTG GCG CAG AGC CTC TTC GCG TAC	268
	Gly Ala Phe Leu Ser Ala His Leu Val Ala Gln Ser Leu Phe Ala Tyr	
25	25 30 35 40	
	CTG GAG CAC CGG CGG GTG GCG GCG GCG GCG CGG GGG CCG CTG GAT GCA	316
	Leu Glu His Arg Arg Val Ala Ala Ala Ala Arg Gly Pro Leu Asp Ala	
	45 50 55	
30	GCC ACC GCG CGC AGT GTG GCG CTG ACC ATC TCC GCC TAC CAG GAG GAC	364
	Ala Thr Ala Arg Ser Val Ala Leu Thr Ile Ser Ala Tyr Gln Glu Asp	
	60 65 70	
35	CCC GCG TAC CTG CGC CAG TGC CTG GCG TCC GCC CGC GCC CTG CTG TAC	412
	Pro Ala Tyr Leu Arg Gln Cys Leu Ala Ser Ala Arg Ala Leu Leu Tyr	
	75 80 85	
40	CCG CGC GCG CGC GTG CGC GTC CTC ATG GTG GTG GAT GGC AAC CGC GCC	460
	Pro Arg Ala Arg Val Arg Val Leu Met Val Val Asp Gly Asn Arg Ala	
	90 95 100	
45	GAG GAC CTC TAC ATG GTC GAC ATG TTC CGC GAG GTC TTC GCT GAC GAG	508
	Glu Asp Leu Tyr Met Val Asp Met Phe Arg Glu Val Phe Ala Asp Glu	
	105 110 115 120	
	GAC CCC GCC ACG TAC GTG TGG GAC GGC AAC TAC CAC CAG CCC TGG GAA	556
	Asp Pro Ala Thr Tyr Val Trp Asp Gly Asn Tyr His Gln Pro Trp Glu	
50	125 130 135	
	CCC GCG GCG GCG GGC GCG GTG GGC GCC GGA GCC TAT CGG GAG GTG GAG	604
	Pro Ala Ala Ala Gly Ala Val Gly Ala Gly Ala Tyr Arg Glu Val Glu	

55

EP 0 893 506 A1

	140	145	150	
	GCG GAG GAT CCT GGG CGG CTG GCA GTG GAG GCG CTG GTG AGG ACT CGC			652
5	Ala Glu Asp Pro Gly Arg Leu Ala Val Glu Ala Leu Val Arg Thr Arg			
	155	160	165	
	AGG TGC GTG TGC GTG GCG CAG CGC TGG GGC GGC AAG CGC GAG GTC ATG			700
10	Arg Cys Val Cys Val Ala Gln Arg Trp Gly Gly Lys Arg Glu Val Met			
	170	175	180	
	TAC ACA GCC TTC AAG GCG CTC GGA GAT TCG GTG GAC TAC GTG CAG GTC			748
	Tyr Thr Ala Phe Lys Ala Leu Gly Asp Ser Val Asp Tyr Val Gln Val			
15	185	190	195	200
	TGT GAC TCG GAC ACA AGG TTG GAC CCC ATG GCA CTG CTG GAG CTC GTG			796
	Cys Asp Ser Asp Thr Arg Leu Asp Pro Met Ala Leu Leu Glu Leu Val			
	205	210	215	
20	CGG GTA CTG GAC GAG GAC CCC CGG GTA GGG GCT GTT GGT GGG GAT GTG			844
	Arg Val Leu Asp Glu Asp Pro Arg Val Gly Ala Val Gly Gly Asp Val			
	220	225	230	
25	CGG ATC CTT AAC CCT CTG GAC TCC TGG GTC AGC TTC CTA AGC AGC CTG			892
	Arg Ile Leu Asn Pro Leu Asp Ser Trp Val Ser Phe Leu Ser Ser Leu			
	235	240	245	
	CGA TAC TGG GTA GCC TTC AAT GTG GAG CGG GCT TGT CAG AGC TAC TTC			940
30	Arg Tyr Trp Val Ala Phe Asn Val Glu Arg Ala Cys Gln Ser Tyr Phe			
	250	255	260	
	CAC TGT GTA TCC TGC ATC AGC GGT CCT CTA GGC CTA TAT AGG AAT AAC			988
	His Cys Val Ser Cys Ile Ser Gly Pro Leu Gly Leu Tyr Arg Asn Asn			
35	265	270	275	280
	CTC TTG CAG CAG TTT CTT GAG GCC TGG TAC AAC CAG AAG TTC CTG GGT			1036
	Leu Leu Gln Gln Phe Leu Glu Ala Trp Tyr Asn Gln Lys Phe Leu Gly			
40	285	290	295	
	ACC CAC TGT ACT TTT GGG GAT GAC CGG CAC CTC ACC AAC CGC ATG CTC			1084
	Thr His Cys Thr Phe Gly Asp Asp Arg His Leu Thr Asn Arg Met Leu			
	300	305	310	
45	AGC ATG GGT TAT GCT ACC AAG TAC ACC TCC AGG TCC CGC TGC TAC TCA			1132
	Ser Met Gly Tyr Ala Thr Lys Tyr Thr Ser Arg Ser Arg Cys Tyr Ser			
	315	320	325	
50	GAG ACG CCC TCG TCC TTC CTG CGG TGG CTG AGC CAG CAG ACA CGC TGG			1180
	Glu Thr Pro Ser Ser Phe Leu Arg Trp Leu Ser Gln Gln Thr Arg Trp			
	330	335	340	
55				

EP 0 893 506 A1

	TCC	AAG	TCG	TAC	TTC	CGT	GAG	TGG	CTG	TAC	AAC	GCG	CTC	TGG	TGG	CAC	1228
	Ser	Lys	Ser	Tyr	Phe	Arg	Glu	Trp	Leu	Tyr	Asn	Ala	Leu	Trp	Trp	His	
5	345					350					355					360	
	CGG	CAC	CAT	GCG	TGG	ATG	ACC	TAC	GAG	GCG	GTG	GTC	TCC	GGC	CTG	TTC	1276
	Arg	His	His	Ala	Trp	Met	Thr	Tyr	Glu	Ala	Val	Val	Ser	Gly	Leu	Phe	
					365					370					375		
10	CCC	TTC	TTC	GTG	GCG	GCC	ACT	GTG	CTG	CGT	CTG	TTC	TAC	GCG	GGC	CGC	1324
	Pro	Phe	Phe	Val	Ala	Ala	Thr	Val	Leu	Arg	Leu	Phe	Tyr	Ala	Gly	Arg	
					380					385				390			
15	CCT	TGG	GCG	CTG	CTG	TGG	GTG	CTG	CTG	TGC	GTG	CAG	GGC	GTG	GCA	CTG	1372
	Pro	Trp	Ala	Leu	Leu	Trp	Val	Leu	Leu	Cys	Val	Gln	Gly	Val	Ala	Leu	
					395				400				405				
20	GCC	AAG	GCG	GCC	TTC	GCG	GCC	TGG	CTG	CGG	GGC	TGC	CTG	CGC	ATG	GTG	1420
	Ala	Lys	Ala	Ala	Phe	Ala	Ala	Trp	Leu	Arg	Gly	Cys	Leu	Arg	Met	Val	
		410					415				420						
	CTT	CTG	TCG	CTC	TAC	GCG	CCC	CTC	TAC	ATG	TGT	GGC	CTC	CTG	CCT	GCC	1468
25	Leu	Leu	Ser	Leu	Tyr	Ala	Pro	Leu	Tyr	Met	Cys	Gly	Leu	Leu	Pro	Ala	
		425				430				435					440		
	AAG	TTC	CTG	GCG	CTA	GTC	ACC	ATG	AAC	CAG	AGT	GGC	TGG	GGC	ACC	TCG	1516
	Lys	Phe	Leu	Ala	Leu	Val	Thr	Met	Asn	Gln	Ser	Gly	Trp	Gly	Thr	Ser	
30					445					450					455		
	GGC	CGG	CGG	AAG	CTG	GCC	GCT	AAC	TAC	GTC	CCT	CTG	CTG	CCC	CTG	GCG	1564
	Gly	Arg	Arg	Lys	Leu	Ala	Ala	Asn	Tyr	Val	Pro	Leu	Leu	Pro	Leu	Ala	
				460					465					470			
35	CTC	TGG	GCG	CTG	CTG	CTG	CTT	GGG	GGC	CTG	GTC	CGC	AGC	GTA	GCA	CAC	1612
	Leu	Trp	Ala	Leu	Leu	Leu	Leu	Gly	Gly	Leu	Val	Arg	Ser	Val	Ala	His	
				475				480					485				
40	GAG	GCC	AGG	GCC	GAC	TGG	AGC	GGC	CCT	TCC	CGC	GCA	GCC	GAG	GCC	TAC	1660
	Glu	Ala	Arg	Ala	Asp	Trp	Ser	Gly	Pro	Ser	Arg	Ala	Ala	Glu	Ala	Tyr	
		490					495				500						
45	CAC	TTG	GCC	GCG	GGG	GCC	GGC	GCC	TAC	GTG	GGC	TAC	TGG	GTG	GCC	ATG	1708
	His	Leu	Ala	Ala	Gly	Ala	Gly	Ala	Tyr	Val	Gly	Tyr	Trp	Val	Ala	Met	
		505				510				515					520		
	TTG	ACG	CTG	TAC	TGG	GTG	GGC	GTG	CGG	AGG	CTT	TGC	CGG	CGG	CGG	ACC	1756
50	Leu	Thr	Leu	Tyr	Trp	Val	Gly	Val	Arg	Arg	Leu	Cys	Arg	Arg	Arg	Thr	
					525					530					535		
	GGG	GGC	TAC	CGC	GTC	CAG	GTG	TGAGTCCAGC	CACGCGGATG	CCGCCTCAAG							

Gly Gly Tyr Arg Val Gln Val

540

5 GGTCTTCAGG GGAGGCCAGA GGAGAGCTGC TGGGCCCCGA GCCACGAACT TGCTGGGTGG 1867
 TTCTCTGGGC CTCAGTTTCC CTCCTCTGCC AAACGAGGGG GTCAGCCCAA GATTCTTCAG 1927
 TCTGGACTAT ATTGGGACTG GGACTTCTGG GTCTCCAGGG AGGGTATTTA TTGGTCAGGA 1987
 10 TGTGGGATTT GAGGAGTGGG GGGGAAGGGG TCCTGCTTTC TCCTCGTTCT TATTTAATCT 2047
 CCATTCTAC TGTGTGATCA GGATGTAATA AAGAATTTTA TTTATTTTCA AAAAAAAAAA 2107
 ACCGGAATTC 2117

15 (2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 32

(B) TYPE: nucleic acid

20 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: Other nucleic acid

25 (A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TGGGGCGGCA AACGTGAGGT CATGTACACA GC

32

30 (2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35

(B) TYPE: nucleic acid

35 (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: Other nucleic acid

40 (A) DESCRIPTION: /desc = "synthetic DNA"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

CACCACAGAG CATTGTATAG CCACTCTCGG AAGTA

35

45 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 543

50 (B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULAR TYPE: Peptide

55

EP 0 893 506 A1

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

	Met	Thr	Trp	Ala	Tyr	Ala	Ala	Gly	Val	Pro	Leu	Ala	Ser	Asp	Arg	Tyr
5	1				5				10					15		
	Gly	Leu	Leu	Ala	Phe	Gly	Leu	Tyr	Gly	Ala	Phe	Leu	Ser	Ala	His	Leu
				20					25					30		
10	Val	Ala	Gln	Ser	Leu	Phe	Ala	Tyr	Leu	Glu	His	Arg	Arg	Val	Ala	Ala
			35					40					45			
	Ala	Ala	Arg	Gly	Pro	Leu	Asp	Ala	Ala	Thr	Ala	Arg	Ser	Val	Ala	Leu
		50				55						60				
15	Thr	Ile	Ser	Ala	Tyr	Gln	Glu	Asp	Pro	Ala	Tyr	Leu	Arg	Gln	Cys	Leu
	65					70					75				80	
	Ala	Ser	Ala	Arg	Ala	Leu	Leu	Tyr	Pro	Arg	Ala	Arg	Val	Arg	Val	Leu
				85					90					95		
20	Met	Val	Val	Asp	Gly	Asn	Arg	Ala	Glu	Asp	Leu	Tyr	Met	Val	Asp	Met
				100					105					110		
	Phe	Arg	Glu	Val	Phe	Ala	Asp	Glu	Asp	Pro	Ala	Thr	Tyr	Val	Trp	Asp
		115					120					125				
25	Gly	Asn	Tyr	His	Gln	Pro	Trp	Glu	Pro	Ala	Ala	Ala	Gly	Ala	Val	Gly
		130					135					140				
	Ala	Gly	Ala	Tyr	Arg	Glu	Val	Glu	Ala	Glu	Asp	Pro	Gly	Arg	Leu	Ala
30		145			150					155				160		
	Val	Glu	Ala	Leu	Val	Arg	Thr	Arg	Arg	Cys	Val	Cys	Val	Ala	Gln	Arg
				165					170					175		
	Trp	Gly	Gly	Lys	Arg	Glu	Val	Met	Tyr	Thr	Ala	Phe	Lys	Ala	Leu	Gly
35				180					185					190		
	Asp	Ser	Val	Asp	Tyr	Val	Gln	Val	Cys	Asp	Ser	Asp	Thr	Arg	Leu	Asp
		195					200					205				
40	Pro	Met	Ala	Leu	Leu	Glu	Leu	Val	Arg	Val	Leu	Asp	Glu	Asp	Pro	Arg
		210				215						220				
	Val	Gly	Ala	Val	Gly	Gly	Asp	Val	Arg	Ile	Leu	Asn	Pro	Leu	Asp	Ser
	225				230					235				240		
45	Trp	Val	Ser	Phe	Leu	Ser	Ser	Leu	Arg	Tyr	Trp	Val	Ala	Phe	Asn	Val
				245					250					255		
	Glu	Arg	Ala	Cys	Gln	Ser	Tyr	Phe	His	Cys	Val	Ser	Cys	Ile	Ser	Gly
			260					265					270			
50	Pro	Leu	Gly	Leu	Tyr	Arg	Asn	Asn	Leu	Leu	Gln	Gln	Phe	Leu	Glu	Ala
			275					280					285			

55

Trp Tyr Asn Gln Lys Phe Leu Gly Thr His Cys Thr Phe Gly Asp Asp
 290 295 300
 5 Arg His Leu Thr Asn Arg Met Leu Ser Met Gly Tyr Ala Thr Lys Tyr
 305 310 315 320
 Thr Ser Arg Ser Arg Cys Tyr Ser Glu Thr Pro Ser Ser Phe Leu Arg
 10 325 330 335
 Trp Leu Ser Gln Gln Thr Arg Trp Ser Lys Ser Tyr Phe Arg Glu Trp
 340 345 350
 15 Leu Tyr Asn Ala Leu Trp Trp His Arg His His Ala Trp Met Thr Tyr
 355 360 365
 Glu Ala Val Val Ser Gly Leu Phe Pro Phe Phe Val Ala Ala Thr Val
 370 375 380
 20 Leu Arg Leu Phe Tyr Ala Gly Arg Pro Trp Ala Leu Leu Trp Val Leu
 385 390 395 400
 Leu Cys Val Gln Gly Val Ala Leu Ala Lys Ala Ala Phe Ala Ala Trp
 25 405 410 415
 Leu Arg Gly Cys Leu Arg Met Val Leu Leu Ser Leu Tyr Ala Pro Leu
 420 425 430
 30 Tyr Met Cys Gly Leu Leu Pro Ala Lys Phe Leu Ala Leu Val Thr Met
 435 440 445
 Asn Gln Ser Gly Trp Gly Thr Ser Gly Arg Arg Lys Leu Ala Ala Asn
 450 455 460
 35 Tyr Val Pro Leu Leu Pro Leu Ala Leu Trp Ala Leu Leu Leu Leu Gly
 465 470 475 480
 Gly Leu Val Arg Ser Val Ala His Glu Ala Arg Ala Asp Trp Ser Gly
 40 485 490 495
 Pro Ser Arg Ala Ala Glu Ala Tyr His Leu Ala Ala Gly Ala Gly Ala
 500 505 510
 45 Tyr Val Gly Tyr Trp Val Ala Met Leu Thr Leu Tyr Trp Val Gly Val
 515 520 525
 Arg Arg Leu Cys Arg Arg Arg Thr Gly Gly Tyr Arg Val Gln Val
 530 535 540
 50

Claims

1. A DNA encoding the following polypeptide (a) or (b):

(a) a polypeptide of a hyaluronan synthase of human origin; and

(b) a partial polypeptide of the polypeptide (a).

2. A DNA encoding any one of the following polypeptides (a) to (c):

(a) a polypeptide having an amino acid sequence shown by SEQ ID NO: 4;

(b) a polypeptide having an amino acid sequence shown by SEQ ID NO: 4, which has a substitution, deletion or insertion of one or more amino acid residues that does not substantially lower an activity of synthesizing hyaluronan; and

(c) a partial polypeptide of the polypeptide (a) or (b).

3. The DNA according to claim 1 or 2, which encodes the whole of an amino acid sequence shown by SEQ ID NO: 4.

4. The DNA according to any one of claims 1 to 3, which has at least a part of a nucleotide sequence shown by SEQ ID NO: 1.

5. The DNA according to any one of claims 1 to 4, which has a nucleotide sequence of from position 149 to position 1777 of a nucleotide sequence shown by SEQ ID NO: 1.

6. A polypeptide of a hyaluronan synthase of human origin or a part thereof, which is encoded by the DNA as defined in any one of claims 1 to 5.

7. The polypeptide according to claim 6, which has an amino acid sequence shown by SEQ ID NO: 4.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP97/01111

A. CLASSIFICATION OF SUBJECT MATTER Int. C1 ⁶ C12N15/56, C12N9/24 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Int. C1 ⁶ C12N15/56, C12N9/24 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPI/L, BIOSIS, CAS ONLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Biochemical and Biophysical Research Communication, <u>222</u> (1996), p. 816-820	1 - 7
A	Biochem. J., <u>237</u> (1986), p. 333-342	1 - 7
A	The Journal of Biological Chemistry, <u>268</u> (26)(1993), p. 19181-19184	1 - 7
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search June 18, 1997 (18. 06. 97)		Date of mailing of the international search report July 1, 1997 (01. 07. 97)
Name and mailing address of the ISA/ Japanese Patent Office Facsimile No.		Authorized officer Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)